Published in Drug Week, November 25th, 2005
In the study, when delivered at a fixed dose, ALTU-135 was well-tolerated and achieved statistically significant improvements in the absorption of fat and protein as well as an overall improvement in the absorption of carbohydrates, all of which are essential for proper nutrition and growth.
The phase II study enrolled 125 patients who were treated at 26 CF centers in the U.S., and the company...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.